More than their sum in your parts: the mechanisms that underpin the mutually advantageous relationship between HIV and sexually transmitted infections

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 4, 2007, Pages 237-246

  Rebbapragada, A ^a   Kaul, R ^a,b,c  

^a Clinical Science Division   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MICROBICIDE;

BLOOD; CELL POPULATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DEATH; DISEASE PREDISPOSITION; DRUG EFFICACY; EPITHELIUM; FEMALE GENITAL SYSTEM; GENITAL TRACT INFECTION; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INNATE IMMUNITY; MUCOSA INFLAMMATION; NONHUMAN; REVIEW; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; UNSAFE SEX; VAGINA FLORA; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 47049120441     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.12.003     Document Type: Review

References (135)

1. (1981) Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men - New York City and California. In MMWR Morb Mortal Wkly Rep 30, 305-308.
2. Gallo R.C., et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220 (1983) 865-867
3. UNAIDS and Organization, W.H. (2007) 2007 AIDS epidemic update. In World Health Organization HIV/AIDS Strategic Information Reports (Vol. 2007)
4. Quinn T.C., and Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 308 (2005) 1582-1583
5. Annan K. Beyond the horizon. Time 160 (2002) A18-A19
6. McMichael A.J., and Hanke T. HIV vaccines 1983-2003. Nat. Med. 9 (2003) 874-880
7. Royce R.A., et al. Sexual transmission of HIV. N. Engl. J. Med. 336 (1997) 1072-1078
8. Cohen M.S. HIV and sexually transmitted diseases: lethal synergy. Top. HIV Med. 12 (2004) 104-107
9. Kaul R., et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J. Reprod. Immunol. 77 (2008) 32-40
10. Sodora D.L., et al. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res. Hum. Retroviruses 14 Suppl. 1 (1998) S119-S123
11. Rousseau C.M., et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J. Infect. Dis. 190 (2004) 1880-1888
12. Weiss R.A. HIV receptors and the pathogenesis of AIDS. Science 272 (1996) 1885-1886
13. Peters P.J., et al. Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J. Virol. 80 (2006) 6324-6332
14. Jameson B., et al. Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J. Virol. 76 (2002) 1866-1875
15. Patterson B.K., et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am. J. Pathol. 153 (1998) 481-490
16. Philpott S.M. HIV-1 coreceptor usage, transmission, and disease progression. Curr. HIV Res. 1 (2003) 217-227
17. Haase A.T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5 (2005) 783-792
18. Maher D., et al. HIV binding, penetration, and primary infection in human cervicovaginal tissue. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11504-11509
19. Hladik F., et al. Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26 (2007) 257-270
20. Geijtenbeek T.B., et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100 (2000) 587-597
21. Belyakov I.M., and Berzofsky J.A. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20 (2004) 247-253
22. Gurney K.B., et al. Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa. J. Virol. 79 (2005) 5762-5773
23. Poles M.A., et al. A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J. Virol. 75 (2001) 8390-8399
24. Soilleux E.J., and Coleman N. Expression of DC-SIGN in human foreskin may facilitate sexual transmission of HIV. J. Clin. Pathol. 57 (2004) 77-78
25. Pudney J., et al. Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol. Reprod. 73 (2005) 1253-1263
26. Coombs R.W., et al. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 17 (2003) 455-480
27. de Witte L., et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat. Med. 13 (2007) 367-371
28. Keller M.J., et al. Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus. J. Antimicrob. Chemother. 51 (2003) 1099-1102
29. 2-generating lactobacilli. J. Infect. Dis. 164 (1991) 94-100
30. Iqbal S., and Kaul R. Mucosal innate immunity as a determinant of HIV susceptibility. Am. J. Reprod. Immunol. 59 (2008) 44-54
31. Shugars D.C. Endogenous mucosal antiviral factors of the oral cavity. J. Infect. Dis. 179 Suppl. 3 (1999) S431-S435
32. Wahl S.M., et al. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I. Oral Dis. 3 Suppl. 1 (1997) S64-S69
33. Ma G., et al. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 200 (2004) 1337-1346
34. Groot F., et al. Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN-gp120 interaction. J. Virol. 79 (2005) 3009-3015
35. Yang D., et al. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 22 (2004) 181-215
36. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3 (2003) 710-720
37. Mackewicz C.E., et al. alpha-Defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 17 (2003) F23-F32
38. Feng Z., et al. Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4. J. Immunol. 177 (2006) 782-786
39. Sun L., et al. Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J. Virol. 79 (2005) 14318-14329
40. Hazrati E., et al. Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J. Immunol. 177 (2006) 8658-8666
41. Buck C.B., et al. Human alpha-defensins block papillomavirus infection. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 1516-1521
42. Iqbal S.M., et al. Trappin-2: discovery of a novel inhibitor of HIV, highly elevated in HIV-resistant sex workers (#WEAA0504). XVI International AIDS Conference. Toronto, ON. Aug 13-18 (2006)
43. Venkataraman N., et al. Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J. Immunol. 175 (2005) 7560-7567
44. Celum C.L. The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 11 Suppl. 1 (2004) 36A-45A
45. Plummer F.A., and Ndinya-Achola J.O. Sexually transmitted diseases and HIV-1: interactions in transmission and role in control programs. East Afr. Med. J. 67 (1990) 457-460
46. Simonsen J.N., et al. Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. N. Engl. J. Med. 319 (1988) 274-278
47. Freeman E.E., et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20 (2006) 73-83
48. Baeten J.M., et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 21 (2007) 1771-1777
49. Kaul R., et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 291 (2004) 2555-2562
50. Draper D.L., et al. Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am. J. Obstet. Gynecol. 183 (2000) 1243-1248
51. Novak R.M., et al. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin. Vaccine Immunol. 14 (2007) 1102-1107
52. Keller M.J., and Herold B.C. Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract. Am J Reprod Immunol 56 (2006) 356-363
53. Farquhar C., et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J. Infect. Dis. 186 (2002) 1173-1176
54. Pillay K., et al. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J. Infect. Dis. 183 (2001) 653-656
55. Valore E.V., et al. Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect. Immun. 74 (2006) 5693-5702
56. Goldenberg R.L., et al. The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am. J. Obstet. Gynecol. 182 (2000) 631-635
57. Eschenbach D.A., et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am. J. Obstet. Gynecol. 158 (1988) 819-828
58. Nugent R.P., et al. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J. Clin. Microbiol. 29 (1991) 297-301
59. Schwebke J.R. Abnormal vaginal flora as a biological risk factor for acquisition of HIV infection and sexually transmitted diseases. J. Infect. Dis. 192 (2005) 1315-1317
60. Taha T.E., et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12 (1998) 1699-1706
61. Taha T.E., et al. HIV infection and disturbances of vaginal flora during pregnancy. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20 (1999) 52-59
62. Martin H.L., et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J. Infect. Dis. 180 (1999) 1863-1868
63. Myer L., et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J. Infect. Dis. 192 (2005) 1372-1380
64. Hill J.A., and Anderson D.J. Human vaginal leukocytes and the effects of vaginal fluid on lymphocyte and macrophage defense functions. Am. J. Obstet. Gynecol. 166 (1992) 720-726
65. Ross S.A., et al. Association between genital tract cytomegalovirus infection and bacterial vaginosis. J. Infect. Dis. 192 (2005) 1727-1730
66. Cherpes T.L., et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin. Infect. Dis. 37 (2003) 319-325
67. Nagot N., et al. Association between bacterial vaginosis and Herpes simplex virus type-2 infection: implications for HIV acquisition studies. Sex Transm. Infect. 83 (2007) 365-368
68. Kaul R., et al. Prevalent Herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. J. Infect. Dis. 196 (2007) 1692-1697
69. Rebbapragada A., et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 21 (2007) 589-598
70. Rouse B.T., et al. Regulatory T cells in virus infections. Immunol. Rev. 212 (2006) 272-286
71. Svanborg C., et al. Cytokine responses during mucosal infections: role in disease pathogenesis and host defence. Curr. Opin. Microbiol. 2 (1999) 99-105
72. Bafica A., et al. Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors. J. Immunol. 172 (2004) 7229-7234
73. Ernst P.B., et al. Regulation of the mucosal immune response. Am. J. Trop. Med. Hyg. 60 Suppl. 4 (1999) 2-9
74. Sturm-Ramirez K., et al. High levels of tumor necrosis factor-alpha and interleukin-1beta in bacterial vaginosis may increase susceptibility to human immunodeficiency virus. J. Infect. Dis. 182 (2000) 467-473
75. Cohen M.S., and Pilcher C.D. Amplified HIV transmission and new approaches to HIV prevention. J. Infect. Dis. 191 (2005) 1391-1393
76. Quinn T.C., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342 (2000) 921-929
77. Sheth P.M., et al. HIV viral shedding in semen: lack of correlation with systemic virus-specific CD8 responses. AIDS 18 (2004) 2202-2205
78. Kovacs A., et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 358 (2001) 1593-1601
79. Brenner B.G., et al. High rates of forward transmission events after acute/early HIV-1 infection. J. Infect. Dis. 195 (2007) 951-959
80. Wawer M.J., et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191 (2005) 1403-1409
81. Pilcher C.D., et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 21 (2007) 1723-1730
82. Pilcher C.D., et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189 (2004) 1785-1792
83. Kreiss J.K., et al. Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. J. Infect. Dis. 160 (1989) 380-384
84. Mbopi-Keou F.X., et al. Genital shedding of herpes simplex virus-2 DNA and HIV-1 RNA and proviral DNA in HIV-1- and herpes simplex virus-2-coinfected African women. J. Acquir. Immune Defic. Syndr. 33 (2003) 121-124
85. Kinter A.L., et al. HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14076-14081
86. Corbett E.L., et al. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 359 (2002) 2177-2187
87. Mosca J.D., et al. Activation of human immunodeficiency virus by herpesvirus infection: identification of a region within the long terminal repeat that responds to a trans-acting factor encoded by herpes simplex virus 1. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 7408-7412
88. McClelland R.S., et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 16 (2002) 2425-2430
89. Sheth P.M., et al. Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation. J. Infect. Dis. 193 (2006) 45-48
90. Speck C.E., et al. Risk factors for HIV-1 shedding in semen. Am. J. Epidemiol. 150 (1999) 622-631
91. McCarthy M., et al. Cytomegalovirus and human herpesvirus-6 trans-activate the HIV-1 long terminal repeat via multiple response regions in human fetal astrocytes. J. Neurovirol. 4 (1998) 495-511
92. Al-Harthi L., et al. Bacterial vaginosis-associated microflora isolated from the female genital tract activates HIV-1 expression. J. Acquir. Immune Defic. Syndr. 21 (1999) 194-202
93. Cohn J.A., et al. HIV-inducing factor in cervicovaginal secretions is associated with bacterial vaginosis in HIV-1-infected women. J. Acquir. Immune Defic. Syndr. 39 (2005) 340-346
94. Anzala A.O., et al. Acute Sexually Transmitted Infections Increase Human Immunodeficiency Virus Type 1 Plasma Viremia, Increase Plasma Type 2 Cytokines, and Decrease CD4 Cell Counts. J. Infect. Dis. 182 (2000) 459-466
95. Nkengasong J.N., et al. Human immunodeficiency virus type 1 (HIV-1) plasma virus load and markers of immune activation among HIV-infected female sex workers with sexually transmitted diseases in Abidjan, Cote d'Ivoire. J. Infect. Dis. 183 (2001) 1405-1408
96. Nagot N., et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356 (2007) 790-799
97. Sheth, P.M. et al. Herpes simplex type 2 infection is associated with impaired HIV-specific T cell responses and systemic immune activation. J. Infect. Dis. (In Press)
98. Kaul R., et al. Gonococcal cervicitis is associated with reduced systemic CD8+ T cell responses in human immunodeficiency virus type 1-infected and exposed, uninfected sex workers. J. Infect. Dis. 185 (2002) 1525-1529
99. Boulton I.C., and Gray-Owen S.D. Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes. Nat. Immunol. 3 (2002) 229-236
100. Yu Q., et al. A dangerous liaison between two major STD pathogens, HIV and Neisseria gonorrhoeae: Opa52 protein of Neisseria gonorrhoeae impairs dendritic cell maturation and subsequent HIV-specific T cell immunity (Abstract #454). Keystone Conference on the Molecular Mechanisms of HIV Pathogenesis (2004)
101. Grosskurth H., et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 346 (1995) 530-536
102. Kamali A., et al. Syndromic management of sexually transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 361 (2003) 645-652
103. Wawer M.J., et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 353 (1999) 525-535
104. Grosskurth H., et al. Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 355 (2000) 1981-1987
105. Chen L., et al. Sexual risk factors for HIV infection in early and advanced HIV Epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies. PLoS ONE 2 (2007) e1001
106. Barton S., et al. The role of anti-HSV therapeutics in the HIV-infected host and in controlling the HIV epidemic. Herpes 12 (2005) 15-22
107. Watson-Jones D., et al. Impact of HSV-2 suppressive therapy on HIV incidence in HSV-2 seropositive women: a randomised controlled trial in Tanzania: Abstract no. MOAC104. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, AUS. July 22-25 (2007)
108. Rohan L.C., et al. Preventing the sexual transmission of HIV-1 with topical microbicides: another piece of the equation. J. Infect. Dis. 196 (2007) 1285-1287
109. Lederman M.M., et al. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat. Rev. Immunol. 6 (2006) 371-382
110. Keller M.J., et al. Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus. Am. J. Reprod. Immunol. 49 (2003) 279-284
111. Phillips D.M., and Maguire R.A. The development of microbicides for clinical use to prevent sexually transmitted diseases. Curr. Infect. Dis. Rep. 4 (2002) 135-140
112. Keller M.J., et al. Topical microbicides for the prevention of genital herpes infection. J. Antimicrob. Chemother. 55 (2005) 420-423
113. Auvert B., et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2 (2005) e298
114. Bailey R.C., et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369 (2007) 643-656
115. Gray R.H., et al. Male circumcision for HIV prevention in men in Rakai Uganda: a randomised trial. Lancet 369 (2007) 657-666
116. McCoombe S.G., and Short R.V. Potential HIV-1 target cells in the human penis. AIDS 20 (2006) 1491-1495
117. Patterson B.K., et al. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am. J. Pathol. 161 (2002) 867-873
118. Van Damme L., et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360 (2002) 971-977
119. van de Wijgert J.H., and Shattock R.J. Vaginal microbicides: moving ahead after an unexpected setback. AIDS 21 (2007) 2369-2376
120. Fichorova R.N., et al. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J. Infect. Dis. 184 (2001) 418-428
121. Klebanoff S.J. Effects of the spermicidal agent nonoxynol-9 on vaginal microbial flora. J. Infect. Dis. 165 (1992) 19-25
122. Cameron D.W., et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 2 (1989) 403-407
123. Celum C., et al. Genital herpes and human immunodeficiency virus: double trouble. Bull. World Health Organ. 82 (2004) 447-453
124. MacDonald K.S., et al. Vitamin A and risk of HIV-1 seroconversion among Kenyan men with genital ulcers. AIDS 15 (2001) 635-639
125. Shin L.Y.Y., et al. The effects of genital infections on HIV susceptibility in women. OHTN Research Conference. Toronto, ON. Nov 19-20 (2007)
126. Rebbapragada A., et al. Perturbations in the vaginal flora of HIV infected women are associated with increased HIV shedding, genital inflammation, and alterations in cervical immune cell populations. OHTN Research Conference. Toronto, ON. Nov 19-20 (2007)
127. Gadkari D.A., et al. HIV-1 DNA shedding in genital ulcers and its associated risk factors in Pune, India. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18 (1998) 277-281
128. Ghys P.D., et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 11 (1997) F85-F93
129. Plummer F.A. Heterosexual transmission of human immunodeficiency virus type 1 (HIV): interactions of conventional sexually transmitted diseases, hormonal contraception and HIV-1. AIDS Res. Hum. Retroviruses 14 Suppl. 1 (1998) S5-S10
130. Cohen C.R., et al. Increased interleukin-10 in the endocervical secretions of women with non-ulcerative sexually transmitted diseases: a mechanism for enhanced HIV-1 transmission?. AIDS 13 (1999) 327-332
131. Kreiss J., et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J. Infect. Dis. 170 (1994) 1597-1601
132. Scott M., et al. Th1 cytokine patterns in cervical human papillomavirus infection. Clin. Diagn. Lab. Immunol. 6 (1999) 751-755
133. Nicol A.F., et al. Distribution of immune cell subsets and cytokine-producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: influence of HIV-1 coinfection. Diagn. Mol. Pathol. 14 (2005) 39-47
134. Stern J.E., et al. Leukocytes in the cervix: a quantitative evaluation of cervicitis. Obstet. Gynecol. 91 (1998) 987-992
135. Yeaman G.R., et al. The mucosal immune system in the human female reproductive tract: potential insights into the heterosexual transmission of HIV. AIDS Res. Hum. Retroviruses 14 Suppl. 1 (1998) S57-S62